尼妥珠单抗联合放化疗治疗局部晚期鼻咽癌的临床观察  

Clinical observation on nimotuzumab combined with radiochemotherapy in locoregionally advanced nasopharyngeal carcinoma

作　　者：刘菊英[1] 陈薇[1] 问静[1] 郭叶松[1] 姜雪松[1] 卞秀华[1] 

机构地区：[1]江苏省肿瘤医院放射治疗科,南京210009

出　　处：《肿瘤研究与临床》2013年第10期696-699,共4页Cancer Research and Clinic

摘　　要：目的 评价尼妥珠单抗联合放化疗治疗局部晚期鼻咽癌的近期疗效和患者不良反应.方法 回顾性分析尼妥珠单抗联合放化疗治疗42例局部晚期鼻咽癌的近期疗效和患者不良反应.所有患者采用调强放疗（IMRT）技术,鼻咽原发灶处方剂量70 ～ 78.2 Gy,32 ～ 37次,41 ～49 d,颈部淋巴结65 ～ 76 Gy,32～37次,41 ～ 49 d；放疗同时每周应用尼妥珠单抗；全身化疗方案以（多西）紫杉醇＋奈达铂（TP）、复方氟尿嘧啶＋奈达铂（FP）及（多西）紫杉醇＋复方氟尿嘧啶＋奈达铂（TFP）为主.结果 主要不良反应为口腔黏膜炎、骨髓抑制、放射性皮炎和口腔干燥.其中1～2级、3级口腔黏膜炎分别有29例（69.0％）、2例（4.8％）,未出现4级黏膜炎；白细胞下降1～2级、3～4级分别为25例（59.5％）、16例（38.1％）,未发生白细胞减少性发热.全组无痤疮型皮疹、过敏反应及治疗相关的死亡.治疗结束后1个月疗效评价,完全缓解（CR）率90.5％（38/42）,部分缓解（PR）率9.5 ％（4/42）,总有效率100％；其中鼻咽原发灶CR率92.9％（39/42）、PR率7.1％（3/42）,颈部阳性淋巴结CR率97.6％（41/42）,PR率2.4％（1/42）.中位随访22.5个月,1年局部区域控制率100％,1年无远处转移生存率92.7％,1年总生存率95.2％.结论 尼妥珠单抗联合放化疗治疗局部晚期鼻咽癌近期疗效良好,不良反应轻微可耐受.Objective To assess the efficacy and safety of nimotuzumab in combination with radiochemotherapy in locoregionally advanced nasopharyngeal carcinoma （NPC）.Methods 42 patients with locoregionally advanced NPC were retrospectively analyzed.They all received the treatment of nimotuzumab in combination with radiochemotherapy.Intensity modulated radiationtherapy （IMRT） was applied and the prescribed radiation dose administered to the primary tumor was between 70 to 79.2 Gy in 32-37 fractions and 41-49 days.The dose administered to lymph nodes was between 65 to 76 Gy in 32-37 fractions and 41-49 days.Nimotuzumab was given weekly during irradiation.All patients received chemotherapy.Results The main adverse events were mucositis,bone marrow suppression,dermatitis and xerostomia.Grade 1 or 2 oropharyngeal mucositis occurred in 29 （69.0 %） patients,and grade 3 in 2 （4.8 %）.Grade 1 or 2,3 or 4 leucopemia occurred in 25 cases （59.5 %）,16 cases （38.1%）,respectively,without occurrence of febrile neutropenia.There was no treatment related death.Complete response （CR） rate was 90.5 % （38/42）,partial response （PR） rate was 9.5 % （4/42） and the total efficiency was 100 %.After a median follow-up of 22.5 months,the 1-year local control rate was 100 %.1-year distant metastasis-free survival rate was 92.7 %.1-year overall survival rate was 95.2 %.Conclusion Nimotuzumab combined with radiochemotherapy was efficient and safe for locoregionally advanced NPC.

关 键 词：鼻咽肿瘤 尼妥珠单抗 放射治疗 化学治疗 

分 类 号：R739.63[医药卫生—肿瘤]